PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast-logo

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Education Podcasts >

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
More Information

Location:

United States

Description:

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Language:

English


Episodes

Michael B. Atkins, MD - Incorporating Cancer Immunotherapies Into the Oncology Treatment Arsenal in Managed Care Settings: Navigating the Complexities of Value Assessment & Cost Optimization in the Era of Immuno-Oncology

1/18/2019
More
Incorporating Cancer Immunotherapies Into the Oncology Treatment Arsenal in Managed Care Settings: Navigating the Complexities of Value Assessment & Cost Optimization in the Era of Immuno-Oncology

Duration:01:12:09

Naiyer Rizvi, MD - The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care

1/18/2019
More
The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care

Duration:00:41:00

Jorge A. Marrero, MD, MS - Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes

1/11/2019
More
Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes

Duration:01:32:05

Steven Brem, MD - Transforming Glioblastoma Management: A MasterClass on Evaluating Newer and Emerging Options in the Precision Medicine and Person-Centered Care Era

1/9/2019
More
Transforming Glioblastoma Management: A MasterClass on Evaluating Newer and Emerging Options in the Precision Medicine and Person-Centered Care Era

Duration:00:54:36

Andre H. Goy, MD - Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management

1/7/2019
More
Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management

Duration:01:12:05

Roy H. Decker, MD, PhD - The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

12/28/2018
More
The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

Duration:00:58:06

Amir T. Fathi, MD - The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care

12/28/2018
More
The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care

Duration:00:42:10

Lynette M. Sholl, MD - Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do

12/19/2018
More
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do

Duration:01:20:49

Kurt Schalper, MD, PhD and Edward B. Garon, MD, MS - Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution

12/14/2018
More
Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution

Duration:00:52:01

Edward B. Garon, MD, MS - Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice

12/7/2018
More
Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice

Duration:01:05:44

Anjali Saqi, MD, MBA and Geoffrey R. Oxnard, MD - Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists

12/7/2018
More
Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists

Duration:00:48:38

Daniel Pallin, MD, MPH - Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department

11/30/2018
More
Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department

Duration:01:05:27

Mark T. Reding, MD - Treatment Innovation in hemophilia A: Integrating Extended Half-Life Replacement Clotting Factors Into Clinical Practice

11/12/2018
More
Treatment Innovation in hemophilia A: Integrating Extended Half-Life Replacement Clotting Factors Into Clinical Practice

Duration:00:38:11

Michael Wang, MD - Integrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care?

10/22/2018
More
Integrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care?

Duration:00:38:42

Nathan H. Fowler, MD - Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL

10/17/2018
More
Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL

Duration:01:16:14

Unraveling the Complex Treatment Landscape of Prostate Cancer: Guidance for Delivering Evidence-Based, Patient-Centered Care

10/15/2018
More
Unraveling the Complex Treatment Landscape of Prostate Cancer: Guidance for Delivering Evidence-Based, Patient-Centered Care

Duration:00:44:56

Johanna C. Bendell, MD - Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Innovative Strategies, and Patient Perspectives on Disease Management

8/8/2018
More
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Innovative Strategies, and Patient Perspectives on Disease Management

Duration:01:06:44

Omid Hamid, MD - Tracing the Arc of Immunotherapy in Melanoma: Insights on the Current Role and Cutting-Edge Uses of Checkpoint Inhibitors for Patient Care

8/6/2018
More
Tracing the Arc of Immunotherapy in Melanoma: Insights on the Current Role and Cutting-Edge Uses of Checkpoint Inhibitors for Patient Care

Duration:01:09:04

George D. Demetri, MD - Making the TRK to Precision Medicine in Cancer: The Promise of Targeting TRK Fusions in Lung, Breast, GI, and Other Tumors

7/30/2018
More
Making the TRK to Precision Medicine in Cancer: The Promise of Targeting TRK Fusions in Lung, Breast, GI, and Other Tumors

Duration:01:10:43

Edward B. Garon, MD, MS - Realizing the Potential of Precision Oncology in Lung Cancer—Challenges and Opportunities: Strengthening the Partnership Between Oncology and Pathology to Make the Most of the Latest Diagnostics and Therapies

7/26/2018
More
Realizing the Potential of Precision Oncology in Lung Cancer—Challenges and Opportunities: Strengthening the Partnership Between Oncology and Pathology to Make the Most of the Latest Diagnostics and Therapies

Duration:01:39:35